Concurrently, imaging data suggest that liraglutide treatment leads to reductions in ovarian volume and antral follicle count (AFC), indicating that ovarian morphology can undergo measurable changes as the metabolic-endocrine environment improves (96, 124, 130)
Slowed Stomach Emptying: GLP-1 slows the rate at which your stomach empties, keeping you fuller for longer and leading to a gradual rise in blood sugar after eating
Researchers comparing non-incretin options can also review the tesofensine protocol and SLU-PP-332 protocol
Among those not currently using GLP-1 medications, 4% of respondents said they have concrete plans to begin using GLP-1 in the next 12 months, while an additional 13% said they are considering starting the medication
Graphical abstract Similar content being viewed by others Introduction Tirzepatide (LY3298176) is the first peptide dual agonist for type 2 diabetes mellitus (T2DM), which targets both GIPR and GLP1R
Harnessing artificial intelligence to predict ovarian stimulation outcomes in in vitro fertilization: scoping review